SCHEMBL17615428

SCHEMBL17615428

CCCCCc1cc(=O)oc2c(C=O)c(O)ccc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 5/20 0.61
GAA P10253 9/20 0.59
ALDH1A1 P00352 8/20 0.59
KDM4E B2RXH2 7/20 0.59
GLA P06280 5/20 0.59
HPGD P15428 5/20 0.59
KMT2A Q03164 4/20 0.59
MEN1 O00255 3/20 0.59
CASP1 P29466 1/20 0.59
CASP7 P55210 1/20 0.59
HSD17B10 Q99714 1/20 0.59
HIF1A Q16665 3/20 0.55
ERAP1 Q9NZ08 2/20 0.54
POLB P06746 1/20 0.47
HSD17B3 P37058 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C19 P33261 1/20 0.47
MCL1 Q07820 2/20 0.46
MAOB P27338 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17615418 0.96 ALDH1A1 (0.63) ERN1GAAALDH1A1KDM4EGLA
SCHEMBL17615425 0.91 ERN1 (0.66) ERN1GAAALDH1A1KDM4EGLA
SCHEMBL17615417 0.87 ERN1 (0.71) ERN1GAAALDH1A1KDM4EGLA
SCHEMBL18074001 0.83 KDM4E (0.62) GAAALDH1A1KDM4EGLAHPGD
SCHEMBL16710500 0.80 GAA (0.69) GAAALDH1A1KDM4EGLAHPGD
SCHEMBL16197777 0.78 ERN1 (0.70) ERN1GAAALDH1A1KDM4EGLA
SCHEMBL31454884 0.77 ALDH1A1 (0.65) GAAALDH1A1KDM4EGLAHPGD
SCHEMBL14398970 0.77 ERN1 (1.00) ERN1GAAALDH1A1KDM4EGLA
SCHEMBL16197973 0.75 ERN1 (0.69) ERN1GAAALDH1A1KDM4EGLA
SCHEMBL15295521 0.74 MCL1 (0.70) GAAALDH1A1KDM4EGLAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160083361-A1 INHIBITORS OF THE IRE-1/XBP-1 PATHWAY AND METHODS OF USING THEREOF H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2016-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160083361-A1 INHIBITORS OF THE IRE-1/XBP-1 PATHWAY AND METHODS OF USING THEREOF XBP1, RRP1B, ERN1 ERN1 3/4885GAA 2533/4885ALDH1A1 2009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.